Figueras-Novoa C, Akutsu M, Murata D, Weston A, Jiang M, Montaner B
EMBO Rep. 2025; .
PMID: 40033051
DOI: 10.1038/s44319-025-00388-7.
Pezzotti G, Yasukochi Y, Ohgitani E, Nakashio M, Shin-Ya M, Adachi T
RSC Chem Biol. 2025; 6(2):182-208.
PMID: 39850321
PMC: 11751685.
DOI: 10.1039/d4cb00237g.
Luczo J, Spackman E
Rev Med Virol. 2024; 35(1):e70012.
PMID: 39730318
PMC: 11680514.
DOI: 10.1002/rmv.70012.
Liu T, Liang L, Zhao P, Lin W, Zhuang Y, Jiang L
Viruses. 2024; 16(8).
PMID: 39205283
PMC: 11359511.
DOI: 10.3390/v16081309.
Figueras-Novoa C, Timimi L, Marcassa E, Ulferts R, Beale R
J Cell Sci. 2024; 137(15).
PMID: 39145464
PMC: 11361636.
DOI: 10.1242/jcs.261031.
Atomic structure of the open SARS-CoV-2 E viroporin.
Medeiros-Silva J, Dregni A, Somberg N, Duan P, Hong M
Sci Adv. 2023; 9(41):eadi9007.
PMID: 37831764
PMC: 10575589.
DOI: 10.1126/sciadv.adi9007.
The M2 proteins of bat influenza A viruses reveal atypical features compared to conventional M2 proteins.
Thompson D, Cismaru C, Rougier J, Schwemmle M, Zimmer G
J Virol. 2023; 97(8):e0038823.
PMID: 37540019
PMC: 10506471.
DOI: 10.1128/jvi.00388-23.
Antiviral Approaches against Influenza Virus.
Kumari R, Sharma S, Kumar A, Ende Z, Mishina M, Wang Y
Clin Microbiol Rev. 2023; 36(1):e0004022.
PMID: 36645300
PMC: 10035319.
DOI: 10.1128/cmr.00040-22.
Unravelling the Immunomodulatory Effects of Viral Ion Channels, towards the Treatment of Disease.
Gargan S, Stevenson N
Viruses. 2021; 13(11).
PMID: 34834972
PMC: 8618147.
DOI: 10.3390/v13112165.
Influenza Viruses: Harnessing the Crucial Role of the M2 Ion-Channel and Neuraminidase toward Inhibitor Design.
Mtambo S, Amoako D, Somboro A, Agoni C, Lawal M, Gumede N
Molecules. 2021; 26(4).
PMID: 33562349
PMC: 7916051.
DOI: 10.3390/molecules26040880.
Influenza Vaccines toward Universality through Nanoplatforms and Given by Microneedle Patches.
Tang S, Zhu W, Wang B
Viruses. 2020; 12(11).
PMID: 33114336
PMC: 7690886.
DOI: 10.3390/v12111212.
SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine.
Tomar P, Arkin I
Biochem Biophys Res Commun. 2020; 530(1):10-14.
PMID: 32828269
PMC: 7305885.
DOI: 10.1016/j.bbrc.2020.05.206.
Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza.
Scott C, Kankanala J, Foster T, Goldhill D, Bao P, Simmons K
PLoS Pathog. 2020; 16(8):e1008716.
PMID: 32780760
PMC: 7418971.
DOI: 10.1371/journal.ppat.1008716.
Dysregulation of M segment gene expression contributes to influenza A virus host restriction.
Calderon B, Danzy S, Delima G, Jacobs N, Ganti K, Hockman M
PLoS Pathog. 2019; 15(8):e1007892.
PMID: 31415678
PMC: 6695095.
DOI: 10.1371/journal.ppat.1007892.
Identification of key hemagglutinin residues responsible for cleavage, acid stability, and virulence of fifth-wave highly pathogenic avian influenza A(H7N9) viruses.
Sun X, Belser J, Yang H, Pulit-Penaloza J, Pappas C, Brock N
Virology. 2019; 535:232-240.
PMID: 31325838
PMC: 7263870.
DOI: 10.1016/j.virol.2019.07.012.
Viroporins in the Influenza Virus.
To J, Torres J
Cells. 2019; 8(7).
PMID: 31261944
PMC: 6679168.
DOI: 10.3390/cells8070654.
Influenza A Virus Cell Entry, Replication, Virion Assembly and Movement.
Dou D, Revol R, Ostbye H, Wang H, Daniels R
Front Immunol. 2018; 9:1581.
PMID: 30079062
PMC: 6062596.
DOI: 10.3389/fimmu.2018.01581.
Direct Visualization of the Conformational Dynamics of Single Influenza Hemagglutinin Trimers.
Das D, Govindan R, Nikic-Spiegel I, Krammer F, Lemke E, Munro J
Cell. 2018; 174(4):926-937.e12.
PMID: 29961575
PMC: 6086748.
DOI: 10.1016/j.cell.2018.05.050.
Beyond Channel Activity: Protein-Protein Interactions Involving Viroporins.
To J, Torres J
Subcell Biochem. 2018; 88:329-377.
PMID: 29900504
PMC: 7122450.
DOI: 10.1007/978-981-10-8456-0_15.
Host Cellular Protein TRAPPC6AΔ Interacts with Influenza A Virus M2 Protein and Regulates Viral Propagation by Modulating M2 Trafficking.
Zhu P, Liang L, Shao X, Luo W, Jiang S, Zhao Q
J Virol. 2016; 91(1).
PMID: 27795429
PMC: 5165196.
DOI: 10.1128/JVI.01757-16.